Who invested in Edgewise Therapeutics

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Pharma

Funding summaryUpdated 26 Oct 2026

$200Mraised across 1 round since 2025, from 1 source

Latest round: Round, $200MApr 2025
Investors: 5

See who backed them

The rounds

Apr 2025
Round$200M
Source recorded

Founders and team

From Edgewise Therapeutics's own website and the SEC filings it signed: 6 on the team.

Michael NofiChief Financial Officer
Arlene MorrisDirector
Christopher MartinDirector
John MooreGeneral Counsel
Laura BregeDirector
Kevin KochExecutive Officer, Directori

On the board, as filediAlan RussellJonathan RootKenneth HarrisonPeter Thompson

Everyone who backed them

RA Capital ManagementPrivate equity1round

Wellington ManagementVC firm1round

Perceptive AdvisorsAsset manager1round

Janus Henderson InvestorsPrivate equity1round

Cormorant Asset ManagementPrivate equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Edgewise Therapeutics

Who invested in Edgewise Therapeutics?

Edgewise Therapeutics's investors include RA Capital Management, Wellington Management, Perceptive Advisors, Janus Henderson Investors and Cormorant Asset Management.

How much has Edgewise Therapeutics raised?

Edgewise Therapeutics has raised $200M across 1 round since 2025.

When did Edgewise Therapeutics last raise?

Edgewise Therapeutics's most recent round was an Undisclosed round of $200M in Apr 2025.

What was Edgewise Therapeutics's biggest round?

Its most recent round, $200M in Apr 2025, is also its largest on record.

Who backed Edgewise Therapeutics first?

Edgewise Therapeutics's first round on record, in Apr 2025, was backed by RA Capital Management, Wellington Management and Perceptive Advisors and 2 others.